Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accelerated Approval Should Be Less 'Wide Open,' Califf Says

Executive Summary

FDA should write more about its interpretation of regs and apply it more consistently across divisions, commissioner says.

Advertisement

Related Content

Sarepta Pressured FDA On Eteplirsen Due To ‘Dire’ Finances, Gave Investors Rosier Picture
FDA's Fears Realized: Sponsors Pitching Investors 'Sarepta Model'
Political Appointees Shouldn't Influence Approval Decisions, Califf Says
No More Sarepta-Like Development, FDA Officials Say
Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Accelerated Approval May Support Smaller Trials In Acute Diseases – FDA
Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119364

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel